Evidence map›Paper›PMID 26377680›Full record

ArticleDiagnostic pathology2015

Down-regulation of microRNA-26a and up-regulation of microRNA-27a contributes to aggressive progression of human osteosarcoma.

Afshin Taheriazam, Reza Bahador, Seyyed Hasan Karbasy, Seyed Mir Mansoor Moazen Jamshidi, Ali Torkaman, Emad Yahaghi, Mohammadreza Shakeri

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Diagnostic pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. [MicroRNA-26a and Tumor].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2017
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Evaluation of gene expression level of CDC5L and MACC1 in poor prognosis and progression of osteosarcoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Afshin TaheriazamDepartment of Orthopedics Surgery, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
Reza BahadorDepartment of Orthopaedic and Trauma Surgery, Birjand University of Medical Sciences, Birjand, Iran.
Seyyed Hasan KarbasyDepartment of Anesthesiology, Birjand University of Medical Sciences, Birjand, Iran.
Seyed Mir Mansoor Moazen JamshidiDepartment of Orthopedics, Zanjan University of Medical Sciences, Zanjan, Iran.
Ali TorkamanDepartment of Orthopedics, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
Emad YahaghiDepartment of Molecular Biology, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mohammadreza ShakeriDepartment of Orthopaedic and Trauma Surgery, Birjand University of Medical Sciences, Birjand, Iran. mshakeri7@yahoo.com.
Birjand University of Medical Sciences · IRBaqiyatallah University of Medical Sciences · IRIran University of Medical Sciences · IRIslamic Azad University Medical Branch of Tehran · IRZanjan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteosarcoma is the most common primary bone malignancy with high local aggressiveness and rapid metastasizing potential, resulting in poor survival. Increasing reports suggest that deregulated microRNAs (miRNAs) might provide novel therapeutic targets for cancers. However, the expression of miR-26a and miR-27a in osteosarcoma need further investigation in clinical samples. In our study, we evaluate the expression of these miRNAs in osteosarcoma tissues and compared with paired adjacent non-tumor bone tissues using RT-qPCR.

methodsTotal RNA was purified from patients with osteosarcoma and noncancerous bone tissues. Real-time PCR was applied to quantify the expression level of miR-26a and miR-27a. Moreover, the correlation of these markers with clinicopathological characteristics was also evaluated in osteosarcoma patients. A cox proportional hazards model was performed to assess multivariate analyses of prognostic values.

resultsOur result suggested that miR-26aexpression level in osteosarcoma bone tissue was significantly lower than that in the paired noncancerous bone tissues. MiR-27a expression was higher in osteosarcoma bone tissue in comparison with paired noncancerous bone tissues. The results indicated that low expression level of miR-26a and high expression of miR-27a were associated with high TNM stage (P = 0.001; P = 0.012), tumor grade (P = 0.007; P = 0.016), and distant metastasis (P = 0.004; P = 0.001). Kaplan-Meier analysis and log-rank test indicated that patients with low expression of miR-26a and high expression of miR-27a had shorter overall survival (log-rank test: P < 0.001). Multivariate Cox proportional hazards model analysis showed that low expression of miR-26a and high expression of miR-27a (P = 0.021; P = 0.011), high TNM stage (P = 0.001; P = 0.003), tumor grade (P = 0.005; P = 0.01), and distant metastasis.(P = 0.002; P = 0.005) were independent prognostic factors for overall survival patients with osteosarcoma cancer.

conclusionsIn conclusion, our findings suggested that expression level of miR-26a and miR-27a contributes to aggressive progression of this malignancy. Therefore, may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients.

Indexed as

AdolescentBiomarkers, TumorBone NeoplasmsChildChild, PreschoolDisease-Free SurvivalDisease ProgressionDown-RegulationFemaleHumansKaplan-Meier EstimateMaleMicroRNAsOsteosarcomaPrognosisProportional Hazards ModelsBiomarkers, TumorMicroRNAsMIRN26 microRNA, humanMIRN27 microRNA, human

Identifiers

PMID26377680
PMCPMC4573687
OpenAlexW2735106091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.